In­nate Phar­ma woos Mond­her Mahjoubi away from As­traZeneca’s can­cer re­search ops to take the helm

France’s In­nate Phar­ma has re­cruit­ed As­traZeneca’s top can­cer spe­cial­ist to its helm. Mond­her Mahjoubi, who’s been the ther­a­peu­tic area head of on­col­o­gy, glob­al prod­uct and port­fo­lio strat­e­gy at As­traZeneca, is tak­ing over from Hervé Brail­ly, who be­comes chair­man of the su­per­vi­so­ry board.

Mahjoubi has been op­er­at­ing at As­traZeneca’s big Med­Im­mune sub­sidiary in Gaithers­burg, MD for the past three years, where it’s been hard at work on dur­val­um­ab, a PD-L1 check­point in­hibitor like­ly des­tined to be the fourth or fifth such im­muno-on­col­o­gy pro­gram to hit the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.